Data has been released from a study of hundreds of PTSD patients in Israel.

 November 27, 2017

Tikun Olam, an Israeli medical marijuana supplier, recently analyzed data from its study of cannabis treatment for 391 PTSD patients and determined that patients experienced overall improvement in their condition.

All 391 of the participants in the study had been medically diagnosed with PTSD, and 79 percent listed PTSD as the indication under which they received their approval for medical cannabis. The majority of participants reported severe PTSD symptoms, including “daily rage attacks,” “daily adverse memories” and recurring pain before starting treatment. Seventy percent were using other prescription medications regularly, and more than 73 percent reported a “bad” or “very bad” quality of life.

After one month of treatment, more than 84 percent of participants reported that the general effect of cannabis helped their condition, and after six months, 77 percent said they saw significant improvement of their condition. Fifty-one percent reported that the cannabis helped their condition immediately.

More than half (53 percent) reported decreasing their other daily medications, and 88 percent reported no negative side effects after six months. Fifty-seven percent said they were very easily able to deal with pain six months after starting treatment, and more than 80 percent of participants said they now had a “very good” or “good” quality of life, with only 1.2 percent reporting that their quality of life was “very bad” at the six-month mark.

More information about Tikun Olam and its studies can be found at www.tikunolam.com.

Top image courtesy of Tikun Olam